2015 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015
DateTitle  
10/05/15Data from Ongoing Study of AVXS-101 in Spinal Muscular Atrophy Type 1 Presented at World Muscle Congress
Brighton, United Kingdom. – October 5, 2015 – AveXis, Inc., a clinical stage gene therapy company developing treatments for rare and life-threatening neurological genetic diseases, presented data from its ongoing Phase 1/2 trial of AVXS-101, the company’s initial product candidate for the treatment of spinal muscular atrophy (SMA) Type 1, at the International Congress of the World Muscle Society in Brighton, United Kingdom.Dr. Jerry R. Mendell, Director of the Center for Gene Therapy at The Rese... 
 Printer Friendly Version
09/16/15AveXis Strengthens Executive Leadership Team with Key Appointments
– Thomas J. Dee, Senior Vice President, Chief Financial Officer – – James J. L’Italien, Ph.D., Senior Vice President, Chief Regulatory and Quality Officer – – Andrew Knudten, Senior Vice President, Manufacturing and Supply Chain – – Sukumar Nagendran, M.D., Senior Vice President and Chief Medical Officer – Chicago, Ill. – September 16, 2015 – AveXis, Inc., a leading gene therapy company developing treatments for rare and life-threatening neurological genetic diseases, today announced rece... 
 Printer Friendly Version
09/08/15AveXis Secures $65 Million in Financing
Company builds investor syndicate comprising leading mutual and biotech funds to advance its spinal muscular atrophy gene therapy programChicago, Ill. – September 8, 2015 – AveXis, Inc., a leading gene therapy company developing treatments for rare and life-threatening neurological genetic diseases, today announced the completion of a $65 million Class D common stock financing. The proceeds will be used to advance the company’s ongoing spinal muscular atrophy (SMA) clinical program and expand ke... 
 Printer Friendly Version
06/23/15AveXis Gains Orphan Drug Designation from the European Medicines Agency for Gene Therapy Treatment in Spinal Muscular Atrophy
Dallas – June 23, 2015 – AveXis, Inc., a leading gene therapy company developing treatments for rare and life-threatening genetic diseases, today announced that the European Medicines Agency (EMA) has granted Orphan Drug designation to its gene transfer therapeutic currently in clinical development in the United States for the treatment of type 1 Spinal Muscular Atrophy (SMA). The company received Orphan Drug designation for SMA in the United States in October 2014.The EMA grants Orphan Drug des... 
 Printer Friendly Version
06/18/15AveXis Appoints Sean P. Nolan as Chief Executive Officer
DALLAS, June 18, 2015 — AveXis, Inc., a leading gene therapy company developing treatments for rare and life-threatening genetic diseases, today announced the appointment of Sean P. Nolan as Chief Executive Officer. He will oversee all functions at AveXis, including clinical, regulatory, finance, operations, sales and marketing, manufacturing and quality assurance. He also will join the company’s Board of Directors. Previously, Mr. Nolan was the Chief Business Officer at InterMune.“We are deligh... 
 Printer Friendly Version
04/30/15AveXis Announces Management Succession Plan
April 30, 2015, Dallas, Texas: AveXis, Inc., a biotechnology company focused on using gene therapy to transform the lives of patients with severe genetic and orphan diseases, today announced that John Carbona has resigned from his position as CEO. Mr. Carbona will remain a Director of AveXis. This announcement is the result of a succession plan that has been in process as AveXis advances the clinical development of its lead program for the treatment of Spinal Muscular Atrophy (SMA).John D. Harke... 
 Printer Friendly Version
03/19/15AveXis EU Ltd. Granted SME Status by the European Medicines Agency
Dallas – March 19, 2015 – AveXis, Inc., a biotechnology company focused on using gene therapy to transform the lives of patients with severe genetic and orphan diseases like Spinal Muscular Atrophy (SMA), today announced that the European Medicines Agency (EMA) has granted AveXis’ wholly owned European subsidiary, AveXis EU Ltd., SME (Small and Medium Sized Business Entities) status.The EMA, recognizing the need to encourage drug development by small biotech companies, established the SME progra... 
 Printer Friendly Version
02/25/15AveXis Announces the Formation of its European Subsidiary, AveXis EU, Ltd.
Dallas – February 25, 2015 – AveXis, Inc., a biotechnology company focused on using gene therapy to transform the lives of patients with severe genetic and orphan diseases like Spinal Muscular Atrophy (SMA), today announced the formation of its EU-based wholly-owned subsidiary, AveXis EU, Ltd. The subsidiary will allow AveXis to move forward with its plans to open clinical trials in the European Union and leverage European Medicines Agency’s programs, such as Orphan Medicinal Product Designation... 
 Printer Friendly Version
01/06/15AveXis Closes its Series C Financing Round with Deerfield Management and Roche Venture Fund
Dallas – January 6, 2015 – AveXis, Inc., a biotechnology company focused on using gene therapy to transform the lives of patients with severe genetic and orphan diseases like Spinal Muscular Atrophy (SMA), today announced it has completed a $10 million financing round led by Deerfield Management and Roche Venture Fund. In conjunction with this financing round, Jonathan Leff of Deerfield and Carole Nuechterlein of Roche Venture Fund will join the Company’s Board of Directors. Proceeds from the fi... 
 Printer Friendly Version
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet